Cognition Therapeutics Reports Phase 2 Results Showing Zervimesine Slows Progression of Dementia with Lewy Bodies
I'm PortAI, I can summarize articles.
Cognition Therapeutics Inc. has reported Phase 2 clinical results for zervimesine (CT1812) in mild-to-moderate dementia with Lewy bodies (DLB). The study, published in Alzheimer’s & Dementia, showed zervimesine improved behavioral, functional, cognitive, and movement measures compared to placebo. It met its primary endpoint of safety and tolerability, with positive effects on cognitive fluctuations and daily living activities. The FDA will meet with Cognition Therapeutics in January 2026 to discuss further clinical studies for zervimesine.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments